MARKET WIREYahoo Finance • 5h ago
Amgen (AMGN) Laps the Stock Market: Here's WhyYahoo Finance report covering Amgen Inc. (AMGN) market action, institutional positioning, and fundamental catalysts.
Why AMGN Stock advanced +1.15% Today — RQD Quant Desk Flash
$466.01 +1.15% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $468.09
Amgen Inc. (AMGN) earns a Roarable Rating of B- (Buy) with 71/100 RQD Confidence. High-quality cash engine (67% profit margin, 15% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
ROARABLE B- • BUY
Cap $249.09B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on AMGN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is AMGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Amgen Inc. (NASDAQ: AMGN) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 71/100 at a spot price of $466.01 (+1.15% 1D, market cap $249.09B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 19/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, AMGN ranks #74 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does AMGN compare to GILD and MRNA in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), AMGN carries a Roarable B- (71/100 RQD), trailing P/E of 32.3x, gross margin of 67.2%, and ROIC of 14.5%. By comparison, GILD (Gilead Sciences Inc.) holds a A- grade (82/100 RQD, P/E 24.1x, ROIC 21.0%, cap $205.35B) and MRNA (Moderna Inc.) posts a C- grade (60/100 RQD, P/E N/A, ROIC -34.1%, cap $88.93B). Among the 5-stock peer group, GILD leads on earnings multiple (24.1x) while GILD leads on capital efficiency (21.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for AMGN?
▼
Per AMGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000318154), Amgen Inc. generated $36.75B in revenue (+10.0% YoY), $7.71B in net income, and $8.10B in free cash flow against $90.59B in total assets and $50.01B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $468.11 (+0.45%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 22% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 71/100 (B-) historically ranked in the Top 14% of excess returns over the next 90 days (+6.8% avg 90D alpha vs SPY • 68.4% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERBUY • B-
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw B+ · Rk C-
Each axis scored 0–20
12M PRICE TARGET CONE+5.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AMGN)Realized 20D OHLCV Swing Band: ±5.2%
Deterministic 5-Pillar Attribution (71/100 Composite)
🔍 WHY AMGN SCORES 71/100 (B-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+19/20 pts (27% of score)
20D Institutional Volume Accumulation (±5.2% realized swing band)
▲ #2 Bullish Driver: Insider Conviction & Share Dilution+15/20 pts (21% of score)
SEC Form 4 / 13F Thermometer: 75% Net Buy • Cannibal Buyback (-2.08% YoY Shares)
▼ #1 Drag / Risk Factor: Macro Regime Fit10/20 pts (-10 pt drag)
Macro rate sensitivity & RSI-14 (67) create a -10 pt regime headwind
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C+$412.84+6.3% Next Q
63
Q2 (-2Q)Grade B-$438.94+2.1% Next Q
66
Q3 (-1Q)Grade B-$447.95+4% Next Q
68
CurrentGrade B-$466.01+6.8% Hist 90D α
71
Trajectory: C+ (63) → B- (71)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the AMGN Bull Thesis Could Fail
Even with a 71/100 (B-) score, AMGN faces multiple-compression risk if 32.3x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Sensitive to high interest rates and tighter Federal Reserve market liquidity.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 64.7% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($420.73) or 200D SMA ($376.09) invalidates the momentum regime and cuts Target Base ($493.27) toward Bear Floor ($382.13).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $AMGN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “AMGN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why AMGN Stock advanced +1.15% Today — RQD Quant Desk Flash
Amgen Inc. (AMGN) advanced +1.15% to $466.01, trading at 95% of its 52-week range ($292.12 – $475.65). High-quality cash engine (67% profit margin, 15% return on capital) with steady institutional support.
- ▸Technical Tape: Trading at 95% of its 52-week range ($292.12 – $475.65) with RSI-14 at 67 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±5.2% around $466.01 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable B- (Buy) backed by 67.2% gross margin and $8.1B annual free cash flow.
Live AMGN Headlines & Catalysts
MARKET WIRETrefis • 8h ago
What Would It Take For Amgen Stock To Move Higher?Trefis report covering Amgen Inc. (AMGN) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingKey • 11h ago
Amgen Stock Forecast: Sjögren’s Trial Success Tests AMGN’s Pipeline OutlookTradingKey report covering Amgen Inc. (AMGN) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo Finance • 14h ago
Amgen (AMGN) Stock Could Be 40% Undervalued On KRAS Market Growth NewsYahoo Finance report covering Amgen Inc. (AMGN) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingKey • 17h ago
Amgen Inc Stock (AMGN) Moved Up by 3.29% on Oct 14: Key Drivers UnveiledTradingKey report covering Amgen Inc. (AMGN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 20h ago
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on ItYahoo Finance report covering Amgen Inc. (AMGN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 23h ago
Amgen (AMGN) and Johnson & Johnson (JNJ) Catch Jim Cramer’s Eye for Different ReasonsYahoo Finance report covering Amgen Inc. (AMGN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Amgen (AMGN) Advances While Market Declines: Some Information for InvestorsYahoo Finance report covering Amgen Inc. (AMGN) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo • 4h ago
RNA Targeting Small Molecule Drug Discovery Market - Global Strategic Business Report: Secure a US$5.3B Market by 2030 as Amgen, AstraZeneca, Roche and Merck Accelerate RNA PipelinesAI-driven screening, RNA-focused libraries and pharma-biotech partnerships accelerate drug discovery and unlock opportunities in oncology, rare diseases and infectious diseases.Dublin, Nov. 02, 2026 (GLOBE NEWSWIRE) -- "
RISK WATCHYahoo • 5h ago
Amgen (AMGN) Gets FDA Warning Letter Over Misleading Vectibix PromotionAmgen (NasdaqGS:AMGN) received an FDA Office of Prescription Drug Promotion warning letter regarding a promotional video for Vectibix. The FDA stated that the Vectibix video omitted key safety information and overstated
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (AMGN Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
AMGN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +43.90%⚡ TESTING RESISTANCE
2026-11-02O $451.8H $466.0L $451.8C $466.0VOL 2.98M
RES: $476.9SUP: $398.8SMA50: $420.7SMA200: $376.1
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
AMGN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
25.0%/yr Implied 5Y Growth
vs. +10.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on AMGN today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for AMGN. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AMGN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AMGN)
Health Care Rank #74 of 1016
⚔️ GILD vs AMGN Full Matrix →
1. Head-to-Head Health Care Peer Comparison (AMGN vs. GILD, MRNA, ARGX, RVMD)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Amgen Inc. (AMGN) ranks #74 by composite RQD confidence (71/100, grade B-) and #9 by equity capitalization ($249.09B). Within this direct 5-issuer industry benchmark cohort, GILD leads on earnings valuation at 24.1x trailing P/E, while GILD leads on capital efficiency and profitability with 21.0% ROIC and 78.8% gross margin. GILD currently holds the highest overall quantitative score in the immediate peer group at 82/100 (A-) compared with AMGN at 71/100 (B-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| AMGN
ACTIVE
Amgen Inc. | B- | 71/100 | 32.3x | 67.2% | 14.5% | +1.15% | $249.09B | Benchmark Subject |
| GILD Gilead Sciences Inc. | A- | 82/100 | 24.1x | 78.8% | 21.0% | +3.06% | $205.35B | /gild-vs-amgn → |
| MRNA Moderna Inc. | C- | 60/100 | — | 55.3% | -34.1% | -0.47% | $88.93B | /mrna-vs-amgn → |
| ARGX argenx SE | C | 63/100 | 32.8x | — | 9.9% | -0.56% | $55.72B | /argx-vs-amgn → |
| RVMD Revolution Medicines Inc. | D+ | 55/100 | — | — | -28.6% | +0.55% | $40.78B | /rvmd-vs-amgn → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000318154In its most recent audited fiscal period (FY2025, filed 2025-12-31), Amgen Inc. (AMGN) reported GAAP revenue of $36.75B (+10.0% vs. FY2024 revenue of $33.42B , and +30.4% cumulative change since FY2023) , GAAP net income of $7.71B, operating cash flow of $9.96B, and free cash flow of $8.10B (-22.1% YoY). On the balance sheet, AMGN closed FY2025 with $90.59B in total assets against $50.01B in total debt (Altman Z-Score: 3.83, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $36.75B | $7.71B | $9.96B | $8.10B | $90.59B | $50.01B |
| FY2024 (FY) | 2024-12-31 | $33.42B | $4.09B | $11.49B | $10.39B | $91.84B | $56.55B |
| FY2023 (FY) | 2023-12-31 | $28.19B | $6.72B | $8.47B | $7.20B | $137.00B | $32.06B |
3. AMGN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs AMGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Amgen Inc. (NASDAQ: AMGN) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 71/100 at a spot price of $466.01 (+1.15% 1D, market cap $249.09B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 19/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, AMGN ranks #74 in composite RQD confidence.
How does AMGN compare to GILD and MRNA in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), AMGN carries a Roarable B- (71/100 RQD), trailing P/E of 32.3x, gross margin of 67.2%, and ROIC of 14.5%. By comparison, GILD (Gilead Sciences Inc.) holds a A- grade (82/100 RQD, P/E 24.1x, ROIC 21.0%, cap $205.35B) and MRNA (Moderna Inc.) posts a C- grade (60/100 RQD, P/E N/A, ROIC -34.1%, cap $88.93B). Among the 5-stock peer group, GILD leads on earnings multiple (24.1x) while GILD leads on capital efficiency (21.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for AMGN?
Per AMGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000318154), Amgen Inc. generated $36.75B in revenue (+10.0% YoY), $7.71B in net income, and $8.10B in free cash flow against $90.59B in total assets and $50.01B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is AMGN trading relative to its 50-day, 200-day, and 52-week technical levels?
AMGN last traded at $466.01 (+1.15% on volume of 3,290,628 shares), positioning the stock +10.76% above its 50-day simple moving average ($420.73) and +23.91% above its 200-day simple moving average ($376.09). Across its 52-week range of $292.12 to $475.65, AMGN sits at the 94.7% percentile with a 14-day RSI of 67.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±5.2% ($441.78 to $490.24).
AMGN Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is AMGN stock moving today?
Why AMGN Stock advanced +1.15% Today — RQD Quant Desk Flash. High-quality cash engine (67% profit margin, 15% return on capital) with steady institutional support.
ROARABLE RATING BRIEF • RQD 71/100 (B-)
✓ STAGE-C NUMBER FIREWALL VERIFIED
AMGN — Amgen Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:08:58Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, AMGN scores 71 out of 100, graded B-, with the verdict "Roarable Buy — Sound Institutional Accumulation." The five pillars are:
- Fundamental Cash Engine (13 / 20): Per the RQD rating, this pillar reflects ROIC of 14.5% and an FCF yield of 3.25%. Investor implication: returns on capital are respectable, but the free-cash-flow yield is modest relative to a roughly $249.09B market cap and a 32.3x trailing P/E, so cash generation alone does not justify the valuation; investors are paying for expected future growth.
- Whale 13F Flow (19 / 20): Per the RQD rating, this is the strongest pillar, indicating institutional accumulation and options positioning. Investor implication: sophisticated holders appear to be building positions, which is a supportive signal, though it does not guarantee future price performance.
- Insider Conviction (15 / 20): Per the RQD rating, SEC Form 4 and Congressional PTR cluster flow is scored as moderately positive. Investor implication: insider activity provides some confidence signal but is not a standalone buy trigger.
- Macro Regime Fit (10 / 20): Per the RQD rating, beta of 0.87 and sector sensitivity produce a below-midpoint score. Investor implication: the stock is less volatile than the broad market (beta below 1.0), which can cushion drawdowns, but the score signals limited tailwind from the current macro regime.
- Forensic Balance Sheet (14 / 20): Per the RQD rating, Altman Z of 3.83, Piotroski F of 8/9, and Debt/Equity of 5.78 combine into a solid but leveraged profile. Investor implication: the Z-score and F-score point to financial health and improving fundamentals, while the high Debt/Equity ratio is a key tradeoff to monitor if rates or refinancing conditions tighten.
Taken together, the 71 score reflects strong institutional interest and a healthy balance-sheet profile, offset by a rich valuation (32.3x P/E TTM, 27.2x EV/EBITDA) and a limited macro tailwind. The valuation tradeoff is the central consideration for a prospective investor.
Snapshot
Recent Catalysts & News Wire Analysis
- Per the news wire, Yahoo Finance reported on AMGN's market action and institutional positioning (flagged YELLOW, market wire).
- Per the news wire, Trefis discussed what would drive the stock higher (flagged YELLOW).
- Per the news wire, TradingKey covered a Sjögren's trial success and its implications for the pipeline outlook (flagged YELLOW).
- Per the news wire, a Yahoo Finance report discussed a possible KRAS market growth opportunity, framed as a potential undervaluation (flagged GREEN, catalyst).
- Per the news wire, TradingKey reported a 3.29% move on Oct 14 with key drivers (flagged YELLOW).
- Per the news wire, Yahoo Finance profiled AMGN as a trending stock (flagged YELLOW).
Risk watch items: the source data does not specify the magnitude of trial outcomes or the timeline of pipeline catalysts. Per the butterfly graph, proprietary signals are none.
Open Questions
- What are the specific products and revenue mix driving the FY 2025 revenue of $36751.0M, and how concentrated is it?
- What is the reported EPS for each period, given that the financials list EPS as N/A?
- What are the timelines, probabilities, and commercial potential of the Sjögren's and KRAS programs referenced in the news?
- How is the $50005.0M debt structured (maturities, rates, covenants), and what drives the 5.78 Debt/Equity ratio?
- What are the upstream and downstream dependencies and any analyst price targets?
AMGN Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Amgen Inc. (AMGN) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 5h ago
Amgen (AMGN) Laps the Stock Market: Here's Why Yahoo Finance report covering Amgen Inc. (AMGN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Trefis • 8h ago
What Would It Take For Amgen Stock To Move Higher? Trefis report covering Amgen Inc. (AMGN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingKey • 11h ago
Amgen Stock Forecast: Sjögren’s Trial Success Tests AMGN’s Pipeline Outlook TradingKey report covering Amgen Inc. (AMGN) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo Finance • 14h ago
Amgen (AMGN) Stock Could Be 40% Undervalued On KRAS Market Growth News Yahoo Finance report covering Amgen Inc. (AMGN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingKey • 17h ago
Amgen Inc Stock (AMGN) Moved Up by 3.29% on Oct 14: Key Drivers Unveiled TradingKey report covering Amgen Inc. (AMGN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 20h ago
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It Yahoo Finance report covering Amgen Inc. (AMGN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 23h ago
Amgen (AMGN) and Johnson & Johnson (JNJ) Catch Jim Cramer’s Eye for Different Reasons Yahoo Finance report covering Amgen Inc. (AMGN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Amgen (AMGN) Advances While Market Declines: Some Information for Investors Yahoo Finance report covering Amgen Inc. (AMGN) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
AMGN Bull vs. Bear Conversation Board — What's Your Call at $466.01?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AMGN 🐻 33% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH
🎯 Target: $543.66 (+18.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is AMGN (B- • RQD 71/100) a Buy at $460.73?
Welcome to the AMGN (Amgen Inc.) Roar Pit. Current RQD Composite is 71/100 (Roarable Buy — Sound Institutional Accumulation) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to capital efficiency (14.5% ROIC), while bears focus on valuation multiple compression (32.3x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $368.58 (-20.0%)
Spot @ $460.73 Pump the brakes on AMGN — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on AMGN, but look at what you are paying: 32.3x trailing P/E with 67.2% gross margins. Unless Amgen Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH
🎯 Target: $589.73 (+28.0%)
Spot @ $460.73 AMGN cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on AMGN, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $460.73 (52-wk range $292.12 - $475.65), any beat on forward guidance forces shorts and underweight funds to chase.